Details

Autor(en) / Beteiligte

• Mohler, James L
• Armstrong, Andrew J
• Bahnson, Robert R
• Boston, Barry
• Busby, J Erik
• D'Amico, Anthony Victor
• Eastham, James A
• Enke, Charles A
• Farrington, Thomas
• Higano, Celestia S
• Horwitz, Eric Mark
• Kantoff, Philip W
• Kawachi, Mark H
• Kuettel, Michael
• Lee, Richard J
• MacVicar, Gary R
• Malcolm, Arnold W
• Miller, David
• Plimack, Elizabeth R
• Pow-Sang, Julio M
• Roach, 3rd, Mack
• Rohren, Eric
• Rosenfeld, Stan
• Srinivas, Sandy
• Strope, Seth A
• Tward, Jonathan
• Twardowski, Przemyslaw
• Walsh, Patrick C
• Ho, Maria
• Shead, Dorothy A

Titel

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

Ist Teil von

• Journal of the National Comprehensive Cancer Network, 2012-09, Vol.10 (9), p.1081

Ort / Verlag

United States

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.